HC Wainwright Rates Hemab Therapeutics (COAG) buy
HC Wainwright maintains its buy rating on COAG with a $40 price target, a 56.80% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Hemab Therapeutics Holdings, Inc. ($COAG) "buy" with a $40 price target on June 17, 2026.
Since the rating, $COAG is up 8.7% after 1 week, up 86.3% after 1 month and up 13.7% to date (from the $26.45 close on Jun 17, 2026).
COAG
Hemab Therapeutics Holdings, Inc.
Key Points
- HC Wainwright reiterated its buy rating on COAG with a $40 price target on June 17, 2026.
- COAG shares traded around $25.51, highlighting analyst optimism with a significant upside potential.
- Other firms like Wedbush and Jefferies also have buy ratings on COAG, with targets ranging from $36 to $50.
Get $COAG trade alerts by text
We text you when insiders, Congress or big funds trade $COAG. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hemab Therapeutics Holdings, Inc. alert may contain errors. Disclosures
On June 17, 2026, HC Wainwright reiterated its buy rating for COAG, setting a price target of $40. This reflects continued confidence in the company's prospects.
Analysts Set New Price Targets
HC Wainwright & Co. maintained its buy rating on COAG with a $40 price target on June 17, 2026. This follows similar actions from other analysts. On May 26, 2026, Wedbush initiated coverage with a buy rating and a $42 target, while Jefferies also initiated with a buy rating and a $39 target. Evercore ISI Group set the highest target at $50, and Goldman Sachs initiated with a buy rating and a $36 target.
Hemab Therapeutics Holdings, Inc. Stock Down 38.1%
Shares of COAG traded near $25.51, indicating that analysts see a significant upside potential. With multiple buy ratings and varied price targets, the stock is attracting attention from investors interested in its growth potential.
$COAG price target
Hemab Therapeutics Holdings, Inc. daily closes and this analyst's $40 target. Not advice.
Bottom Line
HC Wainwright's reiterated buy rating and $40 target for COAG suggest confidence in the company's future. Investors often track such analyst updates for insights into potential stock movements. It's important to remember that these ratings reflect the analysts' views as of the report date and are subject to change.
Related Filing Alerts
Source: HC Wainwright's rating change on $COAG (Jun 17, 2026). Written by software, not financial advice. How we make alerts